Table 1.
Clinicopathologic characteristics of patients with both CTCF and ZFHX3 defects and women with no detectable abnormalities*
| Clinicopathologic feature |
CTCF and ZFHX3 defects (23.3%)(n = 109) No. (%) |
Wild-type (51.0%)(n = 238) No. (%) |
P† |
|---|---|---|---|
| Grade | |||
| 1 | 43 (39.8) | 139 (58.4) | .001 |
| 2 | 33 (30.6) | 70 (29.4) | |
| 3 | 32 (29.6) | 29 (12.2) | |
| Age, y | |||
| <60 | 32 (29.4) | 105 (44.1) | .04 |
| >60 | 77 (70.6) | 133 (55.9) | |
| LVSI | |||
| Present | 46 (44.2) | 70 (29.9) | .04 |
| Absent | 58 (55.8) | 164 (70.1) | |
| Stage | |||
| Early: I & II | 90 (82.6) | 194 (81.9) | ns |
| Advanced: III & IV | 19 (17.4) | 43 (18.1) | |
| Adjuvant therapy | |||
| Yes | 39 (36.1) | 66 (27.7) | ns |
| No | 69 (63.9) | 172 (72.3) | |
| BMI, kg/m2 | |||
| <30 | 35 (38.9) | 71 (33.0) | ns |
| >30 | 55 (61.1) | 144 (67.0) | |
| Race | |||
| White | 89 (81.7) | 209 (87.8) | ns |
| Nonwhite | 20 (18.3) | 29 (12.2) | |
| Events‡ | |||
| Recur/progress | 23 of 107 (21.5) | 28 of 232 (12.1) | |
| Death | 51 of 107 (47.7) | 77 of 232 (33.2) | |
* Defects include samples with mutation or loss of heterozygosity. Forty-six cases uninformative for mutation/loss of heterozygosity status and 29 cases with POLE mutations were excluded. BMI = body mass index; LVSI = lymphovascular space invasion; ns = not significant.
† Significance of grade was determined by chi-squared test. Significance of other variables was determined by Fisher’s exact test. All P values are two-tailed and false discovery rate–adjusted.
‡ Excludes perioperative deaths.